Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04495725 · ClinicalTrials.gov registry record · NA

Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain

A NA study of Chronic Pain and Opioid Use, sponsored by Vireo Health.

Completed
Registry status
NA
Development phase
270
Enrollment target
1
Study location

NCT04495725: Completed NA study of Chronic Pain and Opioid Use, sponsored by Vireo Health.

NCT04495725 is a NA study of Chronic Pain and Opioid Use that has completed, run by Vireo Health. The registered enrollment target is 270 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04495725, a NA study of Chronic Pain and Opioid Use, has completed, sponsored by Vireo Health.

COMPLETED
Registry status
NA
Development phase
270 participants
Enrollment target
1
Study location

Study Summary

This study will examine how discounted vouchers for medical cannabis use affects opioid analgesic use in adults with chronic pain. Our study findings will have critically important implications to shape clinical care and medical cannabis policies.

Primary Outcome

The primary outcome will be cumulative opioid analgesic dose.

Interventions

  • OTHER Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products

Study Locations (1)

New York

  • Vireo Health of New York - Queens

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2020-10-06
Est. Completion 2024-03-13
Phase NA
Vireo Health

2 total trials

What the finished NCT04495725 record still lists

NCT04495725 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (65% lower).

The record links to 3 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products is the first listed.

NCT04495725 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04495725 about?

NCT04495725 is a clinical study titled "Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain". This study will examine how discounted vouchers for medical cannabis use affects opioid analgesic use in adults with chronic pain. Our study findings will have critically important implications to shape clinical care and medical cannabis policies.

What is the current status of trial NCT04495725?

This trial is currently completed. It is a NA study. The enrollment target is 270 participants. The study started on 2020-10-06. Estimated completion is 2024-03-13.

What conditions does trial NCT04495725 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use, Marijuana.

What interventions are being tested in trial NCT04495725?

The interventions under investigation include: Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products (OTHER).

Who is sponsoring clinical trial NCT04495725?

This trial is sponsored by Vireo Health, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04495725 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04495725's enrollment target sits among peer trials

270 59th of 301 higher than 243 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04495725, the US trial registry maintained by the National Library of Medicine. NCT04495725 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.